New research, presented at a major cardiology congress, is set to inform best practice in cardiovascular care, with the aim of improving outcomes and reducing mortality. The Clinical Services Journal highlights some key findings.
Novel findings were revealed in more than 3,750 abstracts and clinical cases presented by scientists, from 86 countries, at the Annual Congress of the European Society of Cardiology.
Practice-changing research was presented including new findings from major studies. Among these included the findings from STEPHFpEF, the first trial of a pharmacologic agent to specifically target obesity as a treatment strategy for heart failure with preserved ejection fraction. The study indicated that obesity is a target for therapeutic intervention in this vulnerable patient group
he results of NOAH-AFNET 6 were also presented, which showed that anticoagulants cause bleeding without preventing stroke in patients with atrial high-rate episodes (AHRE), but without electrocardiogram (ECG)-diagnosed atrial fibrillation. The results of this major trial suggest that ECG documentation of atrial fibrillation is needed before starting oral anticoagulation in patients with AHRE
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.
